Vir Biotechnology (VIR)
(Delayed Data from NSDQ)
$7.63 USD
-0.09 (-1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $7.64 +0.01 (0.13%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.63 USD
-0.09 (-1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $7.64 +0.01 (0.13%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Zacks News
IMV Doses First Patient in the Mid-Stage Study With Keytruda
by Zacks Equity Research
IMV (IMV) doses first patient in the phase II study evaluating lead compound, maveropepimut-S (MVP-S), in combination with Keytruda
Vir Biotechnology, Inc. (VIR) Soars 15.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Vir Biotechnology, Inc. (VIR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Vir Biotechnology, Inc. (VIR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Glaxo (GSK) & Vir to Supply More COVID Antibody Doses in US
by Zacks Equity Research
The U.S. government enters into an agreement with Glaxo (GSK) and Vir Biotechnology (VIR) to procure an additional 600,000 doses of sotrovimab for early treatment of COVID-19.
Gilead (GILD) Partners With Merck for Keytruda in NSCLC Study
by Zacks Equity Research
Gilead (GILD) and Merck collaborate to evaluate the former's breast cancer drug in combination with the latter's blockbuster drug Keytruda for NSCLC study.
Regeneron (REGN) Collaborates With Ultragenyx for Evkeeza
by Zacks Equity Research
Regeneron (REGN) teams up with Ultragenyx Pharmaceutical to commercialize and distribute Evkeeza (evinacumab) outside the United States.
Implied Volatility Surging for Vir Biotechnology (VIR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Vir Biotechnology (VIR) stock based on the movements in the options market lately.
GILD or VIR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GILD vs. VIR: Which Stock Is the Better Value Option?
Biotech Stock Roundup: Regulatory Updates From BIIB, AMGN and NVAX & More
by Zacks Equity Research
Regulatory and other pipeline updates from Biogen (BIIB) and Novavax (NVAX) have been the biotech sector's few key highlights during the past week.
Gilead's (GILD) Veklury Gets EC Nod for Use in Early COVID-19
by Zacks Equity Research
Gilead's (GILD) Veklury can now be used in the EU at the early stages of COVID-19 to help prevent disease progression in high-risk patients.
Vir (VIR), Glaxo's Xevudy Wins EC Approval for COVID-19
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) and partner GlaxoSmithKline obtain the European Commission's nod for Xevudy for the early treatment of COVID-19.
Omicron Variant Puts COVID-19 Antibody Treatments in Focus
by Zacks Equity Research
We take a look at the data reported so far on antibody treatments by Regeneron (REGN), AstraZeneca (AZN) and Vir (VIR) amid the Omicron variant scare. The results have been mixed mostly.
Glaxo (GSK), Medicago COVID-19 Jab Effective Against Variants
by Zacks Equity Research
Glaxo (GSK) and Medicago's plant-based vaccine achieves more than 70% efficacy rate against COVID-19 and its major variants.
Biotech Stock Roundup: ACAD Up on Study Results, BHVN's Pipeline Update & More
by Ekta Bagri
Acadia's (ACAD) study results and other pipeline updates have been the biotech sector's few key highlights during the past week.
Anixa (ANIX) COVID Compounds Prove Effective Against Omicron
by Zacks Equity Research
Anixa Biosciences' (ANIX) potential COVID-19 compounds show effectiveness against the Omicron variant of COVID-19.
Lilly (LLY) COVID-19 Antibody Gets FDA Nod for Use in Kids
by Zacks Equity Research
With the approval in children and infants, Lilly's (LLY) bamlanivimab with etesevimab can now be given as treatment and prevention options to high-risk individuals of any age.
Glaxo (GSK), Vir COVID Drug Appears Effective Against Omicron
by Zacks Equity Research
Glaxo (GSK) and Vir Biotechnology announce promising pre-clinical data from the study of their antibody candidate, sotrovimab, against mutations found in the Omicron variant.
Pharma Stock Roundup: FDA Panel Vote for MRK COVID Pill, JNJ Omicron Jab Plan
by Kinjel Shah
FDA panel votes for Merck's (MRK) COVID-19 antiviral pill. AbbVie (ABBV) seeks approval for Skyrizi for Crohn's disease in Europe
Company News for Nov 29, 2021
by Zacks Equity Research
Companies in the news are: ISPC, APVO, VIR, CARS
Pfizer (PFE) Inks $5.3B COVID Pill Supply Deal With U.S.
by Zacks Equity Research
The U.S. government is set to purchase 10 million treatment courses of Pfizer's (PFE) oral pill for COVID-19, Paxlovid, if approved or authorized.
Glaxo (GSK), Vir to Supply COVID Drug Sotrovimab to Government
by Zacks Equity Research
Glaxo (GSK) and Vir Biotechnology (VIR) sign purchase contract with the U.S. government to supply doses of sotrovimab worth approximately $1 billion by next month.
4 Reasons Why You Should Add Glaxo (GSK) to Your Portfolio
by Zacks Equity Research
Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2021/2022, which should boost the top line in the long term
Glaxo (GSK), Vir Intramuscular Sotrovimab Meets Study Endpoint
by Zacks Equity Research
Glaxo (GSK) and Vir announce non-inferiority of intramuscular administration of sotrovimab compared to intravenous administration in reducing hospitalization or death as an early treatment of mild-to-moderate COVID-19.
Regeneron (REGN), Roche Get EC Nod for COVID-19 Cocktail
by Zacks Equity Research
Regeneron (REGN) and partner Roche win the European Commission's approval for antibody cocktail to treat and prevent COVID-19.
Regeneron (REGN)-Roche COVID-19 Cocktail Gets Positive CHMP Opinion
by Zacks Equity Research
Regeneron (REGN) and partner Roche obtain a positive opinion from CHMP for their antibody cocktail for the treatment of non-hospitalized patients with confirmed COVID-19 and to prevent the disease.